News Focus
News Focus
icon url

Jackxkr

11/16/24 8:21 PM

#732586 RE: LessIsMore #732585

Yup doesn't look good for that one , keeping spirits up here is hard.
icon url

theorysuit

11/16/24 8:47 PM

#732589 RE: LessIsMore #732585

Repeat the same bullshit many years later thinking people forgot. Well there is a whole set of new retail to fool again.
icon url

Investor082

11/16/24 9:21 PM

#732593 RE: LessIsMore #732585

Interesting, thanks! I wonder if Merck PR’d this news in 2017? I suspect this will be similar.

Why would a big pharma pay $250-300M (for limited to no stake) when they can potentially buy the company at about a billion. That would still be 4 X premium from the current share price. How do they justify that to their board? More importantly, as I mentioned, big pharma wouldn’t allow NWBO to put a statement in 10Q and get ahead of them when the milestone may be another month out. Opens them up to insider trading allegations, competitor disrupting their plans, etc.

By the way, who all were pumping this news that are still around on this platform?
icon url

theorysuit

11/17/24 11:26 AM

#732639 RE: LessIsMore #732585

There is no evidence at all for this trial. This was another carrot that never amounted to anything....actually this was a boldface lie in the form of a PR. Typical NWBO BS. Keep speculation alive on make believe deals.....until it is in writing and not just a PR.....nothing burger given their sordid history on non execution.

https://nwbio.com/nw-bio-announces-phase-ii-clinical-trial-program-combining-dcvax-l-and-pembrolizumab-keytruda-for-colorectal-cancer/